US · BLTE
Belite Bio, Inc
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Diego, CA 92121
- Website
- belitebio.com
Price · as of 2024-12-31
$154.85
Market cap 6.64B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | $32.10 | ||||
| 2023 | $46.05 | ||||
| 2024 | $63.19 |
AI valuation
Our deep-learning model estimates Belite Bio, Inc's (BLTE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $154.85
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BLTE | Belite Bio, Inc | $154.85 | 6.64B | — | — | — | — | -53.39 | 13.23 | — | -50.05 | — | 13.61 | 0.00% | — | — | -30.60% | -1830.90% | -29.29% | 0.00 | -1999.80 | 24.31 | 24.09 | 0.87 | -84.00% | — | -172.00% | -1.52% | -4.83 | -1345.16% | 0.00% | 0.00% | 0.00% | -44.63 | -60.75 | — | 182.72 |
| ACAD | ACADIA Pharmaceuticals In… | $24.56 | 4.16B | +74% | +42% | -54% | +114% | 12.85 | 3.97 | 3.04 | 22.02 | — | 4.75 | 91.46% | 24.10% | 23.64% | 38.89% | 513.41% | 23.39% | 0.07 | — | 2.38 | 2.18 | -2.67 | -46757.00% | 3185.00% | -77327.00% | 5.40% | 0.40 | 398.52% | 0.00% | 0.00% | 4.68% | 9.56 | 14.03 | 2.30 | 3.24 |
| ADMA | ADMA Biologics, Inc. | $15.57 | 3.71B | +161% | +134% | -67% | +6% | 26.89 | 8.28 | 7.74 | 19.93 | — | 8.35 | 57.39% | 37.53% | 28.80% | 35.56% | 38.62% | 26.40% | 0.17 | 26.93 | 6.71 | 3.54 | -0.04 | -2593.00% | 1963.00% | -7473.00% | 0.70% | 0.72 | 6.98% | 0.00% | 0.00% | 0.81% | 20.60 | 141.74 | 7.73 | 18.36 |
| ARQT | Arcutis Biotherapeutics, … | $26.97 | 3.3B | +86% | +93,044% | -97% | — | -195.17 | 16.63 | 8.38 | 1183.71 | — | 18.04 | 90.24% | -3.25% | -4.29% | -9.30% | -163.75% | -4.13% | 0.03 | -1.01 | 3.17 | 2.83 | -14.77 | -8879.00% | 9134.00% | -9438.00% | -0.20% | -0.04 | -84.52% | 0.00% | 0.00% | 2.41% | -240.09 | -465.16 | 7.81 | 5.64 |
| CRNX | Crinetics Pharmaceuticals… | $41.10 | 4.21B | +36% | -54% | — | — | -8.22 | 3.86 | 705.95 | -6.17 | -24.08 | 3.86 | 80.15% | -9534.48% | -8585.18% | -40.17% | -2936.77% | -36.34% | 0.05 | — | 12.32 | 12.09 | 0.11 | 3415.00% | 42166.00% | 6695.00% | -10.03% | -4.44 | -2180.46% | 0.00% | 0.00% | 0.00% | -5.51 | -7.42 | 525.26 | 14.87 |
| DYN | Dyne Therapeutics, Inc. | $15.62 | 2.57B | — | — | — | — | -3.68 | 1.85 | — | -1.74 | — | 1.85 | 0.00% | — | — | -88.03% | -9599.05% | -74.14% | 0.04 | — | 15.60 | 15.20 | 1.31 | -1468.00% | — | 5604.00% | -25.25% | -6.92 | -8227.36% | 0.00% | 0.00% | 27.18% | -1.60 | -1.86 | — | 8.91 |
| LGND | Ligand Pharmaceuticals In… | $198.31 | 3.9B | +75% | -16% | -66% | +114% | 31.47 | 3.85 | 14.61 | 22.87 | — | 5.67 | 97.54% | 17.61% | 46.42% | 13.47% | 5.61% | 9.95% | 0.44 | -10.01 | 22.23 | 21.18 | -1.77 | -288636.00% | 6040.00% | -3682.00% | 1.25% | 1.32 | 7.43% | 0.00% | 0.00% | 5.54% | 77.01 | 74.32 | 13.56 | 5.21 |
| MIRM | Mirum Pharmaceuticals, In… | $92.29 | 4.77B | -16% | +4,973% | -96% | — | -193.57 | 14.37 | 8.67 | 259.00 | — | 84.11 | 80.71% | -4.25% | -4.48% | -8.65% | -8.65% | -3.09% | 1.01 | -1.54 | 2.67 | 2.46 | 1.20 | -7459.00% | 5474.00% | 48801.00% | 1.21% | 0.27 | 21.44% | 0.00% | 0.00% | 1.65% | -201.32 | 81.21 | 8.55 | 5.05 |
| PRAX | Praxis Precision Medicine… | $336.75 | 7.12B | -61% | — | — | — | -24.53 | 8.47 | — | -22.57 | -76.60 | 8.47 | 0.00% | — | — | -45.83% | -195.82% | -42.68% | 0.00 | — | 10.22 | 10.03 | 1.18 | 3203.00% | -10000.00% | 8908.00% | -3.35% | -4.17 | -149.55% | 0.00% | 0.00% | 1.92% | -20.97 | -27.46 | — | 72.54 |
| SLNO | Soleno Therapeutics, Inc. | $39.07 | 2.1B | — | -51% | -73% | — | 99.43 | 4.61 | 10.91 | 62.51 | — | 4.66 | 98.58% | 7.85% | 10.97% | 6.01% | 19.44% | 4.67% | 0.01 | 2.73 | 5.80 | 5.44 | -2.38 | -10890.00% | — | -16741.00% | 2.25% | 0.76 | 60.75% | 0.00% | 0.00% | 6.38% | 118.68 | 37.97 | 9.32 | 10.94 |
| VKTX | Viking Therapeutics, Inc. | $33.84 | 3.91B | — | — | — | — | -10.44 | 5.88 | — | -7.76 | -4.84 | 5.88 | 0.00% | — | — | -47.34% | 896.45% | -44.29% | 0.00 | -7023.96 | 9.33 | 9.21 | 0.42 | 21584.00% | — | 21745.00% | -7.42% | -3.64 | 635.14% | 0.00% | 0.00% | 3.73% | -7.76 | -10.95 | — | 27.00 |
About Belite Bio, Inc
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
- CEO
- Yu-Hsin Lin
- Employees
- 25
- Beta
- -1.46
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $154.85) − 1 = — (DCF, example).